Business
Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights
PALO ALTO, Calif., May 15, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and
About this update from Kodiak Sciences Inc
[{"type":"text","content":"PALO ALTO, Calif., May 15, 2023 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended March 31, 2023.\n\"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly,\" said Victor Perlroth, MD, Chief Executive Officer of Kodiak Sciences. \"Our regulatory strategy for tarcocimab tedromer is built on meeting the primary endpoint in two studies in diabetic eye disease (our GLEAM and GLIMMER studies in diabetic macular edema) and then meeting the primary endpoint in a single study in each of the other major retinal vascular diseases.\"\nDr. Perlroth continued, \"Durability clearly matters to the community of retina patients, physicians and payers, and especially so in diabetic eye disease where many patients are working age and require good vision to maintain their livelihood. One third of anti-VEGF treated diabetic patients discontinue treatment each year, and so the promise of the anti-VEGF mechanism is not realized. Three out of our four ongoing Phase 3 studies of tarcocimab tedromer (tarcocimab, KSI-301) are in diabetic eye disease and are exploring 6-month dosing, the longest treatment interval that has been studied by any intravitreal biologic. If successful, we believe tarcocimab can be an important medicine for the 37 million people living with diabetes in the U.S. who are at risk of developing diabetic eye disease and losing vision.\"\nRecent Business Highlights\nTarcocimab pivotal program: We continued our ongoing Phase 3 studies of tarcocimab towards their primary endpoint readouts. The tarcocimab clinical program explores the potential for 6-month durability in patients with diabetic eye disease through the GLEAM and GLIMMER Phase 3 studies in diabetic macular edema (\"DME\") and the GLOW Phase 3 study in non-proliferative diabetic retinopathy (\"NPDR\") without DME. The tarcocimab clinical progra...